Halozyme Therapeutics Inc (HALO)

Inventory turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cost of revenue (ttm) US$ in thousands 194,942 205,185 210,582 203,283 192,361 182,183 174,679 158,552 139,304 118,771 90,041 79,116 81,413 86,098 73,077 55,799 43,367 33,782 50,547 46,684
Inventory US$ in thousands 141,860 131,412 159,312 168,541 127,601 128,921 132,406 107,521 100,123 103,276 97,615 47,761 53,908 55,978 58,554 58,343 60,747 57,697 48,271 41,452
Inventory turnover 1.37 1.56 1.32 1.21 1.51 1.41 1.32 1.47 1.39 1.15 0.92 1.66 1.51 1.54 1.25 0.96 0.71 0.59 1.05 1.13

December 31, 2024 calculation

Inventory turnover = Cost of revenue (ttm) ÷ Inventory
= $194,942K ÷ $141,860K
= 1.37

Halozyme Therapeutics Inc's inventory turnover ratio has shown fluctuations over the past few years, indicating varying efficiency in managing its inventory levels. The ratio was relatively low at 0.59 on September 30, 2020, suggesting a longer time for the company to sell through its inventory. However, there was a notable improvement in efficiency as the ratio increased to 1.66 on March 31, 2022, indicating that the company was able to turn over its inventory more quickly.

Subsequently, the ratio fluctuated around the 1.3 to 1.5 range from March 2023 to December 2024, which is generally considered healthy for most industries. This suggests that Halozyme Therapeutics Inc was able to efficiently manage its inventory levels during this period.

Overall, while there were some fluctuations in the inventory turnover ratio, the general trend indicates an improvement in inventory management efficiency for Halozyme Therapeutics Inc over the analyzed period.